Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis

Fig. 1

ALS-derived fibroblasts show increased activation-related pathways. Protein lysates of fibroblasts from controls (Ctrl), ALS patients with no known ALS variants (uvALS), and C9orf72 ALS patients were analyzed by Western blot using anti-S100A4, anti-mTOR, anti-SQSTM1/p62, anti-p-NF-κB and anti-NF-κB. GAPDH was used to normalize samples. The expression levels were calculated by densitometric analyses. Data represent mean ± SEM. n = 5 individuals per control fibroblasts and n = 3 per each group of ALS fibroblasts, experiments repeated in triplicate; One-way ANOVA with Tukey correction between Ctrl and uvALS and C9orf72. F value (DFn, DFd): (2, 8) = 18.22 (S100A4), (2, 8) = 14.19 (mTOR), (2, 8) = 51.36 (SQSTM1/p62), (2, 8) = 4.103 (p-NFκB), (2, 8) = 4.445 (NFκB); *p < 0.05,**p < 0.01, and ***p < 0.001 vs. control fibroblasts

Back to article page